COVID-19 has highlighted that South Africa should not be totally reliant on large pharma companies in order to save its people from disease and death. South Africa needs to have domestic companies that are capable of developing treatments for COVID-19 in order to save lives and to assist with turning COVID-19 from a dreaded disease into one that is easily treatable so that the economy can grow again and new jobs created. It is time for South Africans to change the current status quo. The launch of the new South African based and registered biotech company COVID IMPILO provides an opportunity to do just that.
COVID IMPILO has the therapeutic use rights to a special antibody that can potently neutralize the COVID-19 virus, including the South African Variant and stop it from infecting cells. Our special antibody has undergone rigorous independent testing by scientists at the centre for virus research at the University of Glasgow in the UK and also at the Africa Health Research Institute in Duban, South Africa. The results of their tests have been published in scientific publication that can be accessed here https://www.biorxiv.org/content/10.1101/2021.04.11.439360v1
Due to the very high potency of the antibody and its ability to neutralize many different variants of COVID19 this antibody is one of the most promising treatment options for COVID19 globally. This special antibody was developed by fellow South African based biotech company, Afrobodies (www.afrobodies.com), who worked hard throughout the lockdown period in order to develop this world class product.
COVID IMPILO is now focused on putting this highly potent neutralizing antibody into an easy to use inhaler/nebuliser device. This format will allow people who test positive for COVID-19 to use it in the comfort of their own home in order to inhale the treatment. Starting treatment early will stop the disease from progressing and thus avoid hospital visits and possible death.
To bring this treatment to the people of South Africa and the world, COVID IMPILO is turning to the crowd for help. COVID IMPILO is issuing 10,000 shares in the company at 500 ZAR a share in order to raise the first 5 million ZAR. Anyone can buy a share or as many of the 10,000 as they want. It is a first come first served basis.
The money will be spent on further testing to be done at the University of Capetown so that we the crowd can get more quickly to the day it can be given to COVID-19 patients and save lives.
Now the question is do you want to be a part of the crowd that makes history and save lives.
For more information on the share purchase please email our CEO Dr Peter Durcan at ceo@covidimpilo.co.za